

# Assessment of the arterial input function for estimation of coronary flow reserve by single photon emission computed tomography: comparison of two different approaches

Giovanni Storto · Andrea Soricelli · Teresa Pellegrino ·  
Mario Petretta · Alberto Cuocolo

Received: 18 March 2009 / Accepted: 21 May 2009 / Published online: 13 June 2009  
© Springer-Verlag 2009

## Abstract

**Purpose** Attempts to estimate coronary flow reserve (CFR) with single photon emission computed tomography (SPECT) tracers have been recently made. We compared two different methods for the estimation of CFR by SPECT imaging.

**Methods** Fourteen patients with coronary artery disease underwent dipyridamole  $^{99m}\text{Tc}$ -sestamibi SPECT and intracoronary Doppler within 5 days. Myocardial blood flow (MBF) was estimated by measurement of first transit counts in the right pulmonary artery (PA) and left ventricular (LV) chamber, and myocardial counts from SPECT images. Estimated CFR was expressed as the ratio of stress MBF to rest MBF.

**Results** Rest and stress MBF obtained using first transit counts from PA were higher compared to that from LV

chamber (rest:  $1.05 \pm 0.38$  vs  $0.87 \pm 0.34$  counts/pixel per s, respectively,  $p < 0.01$  and stress:  $1.34 \pm 0.45$  vs  $0.91 \pm 0.20$  counts/pixel per s, respectively,  $p < 0.05$ ). In the study vessels, CFR by Doppler was  $1.39 \pm 0.42$ , and SPECT CFR obtained using first transit counts from PA and LV chamber were  $1.36 \pm 0.43$  and  $1.16 \pm 0.39$ , respectively ( $p$  across categories NS). A significant relationship between SPECT CFR obtained using first transit counts from PA and CFR by Doppler was found ( $r = 0.85$ ,  $p < 0.001$ ). No relationship between SPECT CFR obtained using first transit counts from LV chamber and CFR by intracoronary Doppler was observed ( $r = 0.43$ ,  $p = \text{NS}$ ).

**Conclusion** SPECT-estimated CFR obtained using first transit counts from right PA is more accurate and correlates better with the results of intracoronary Doppler than estimated CFR obtained using arterial input function from LV chamber.

G. Storto  
IRCCS, CROB,  
Rionero in Vulture, Italy

A. Soricelli  
SDN Foundation,  
Institute of Diagnostic and Nuclear Development,  
Naples, Italy

T. Pellegrino · A. Cuocolo (✉)  
Department of Biomorphological and Functional Sciences,  
Institute of Biostructures and Bioimages,  
National Council of Research, University Federico II,  
Naples, Italy  
e-mail: cuocolo@unina.it

M. Petretta  
Department of Clinical Medicine,  
Cardiovascular and Immunological Sciences,  
University Federico II,  
Naples, Italy

**Keywords** Coronary flow reserve · Sestamibi imaging ·  
Arterial input function

## Introduction

The assessment of myocardial ischaemia is crucial to decide which type of work-up is indicated in patients with coronary artery disease (CAD). Single photon emission computed tomography (SPECT) myocardial perfusion imaging represents a validated diagnostic tool for the evaluation of patients with suspected or known CAD [1–4]. Nevertheless, it retains some boundaries due to a limited quantitative capability, especially in patients with diffuse CAD [5, 6]. Measurement of coronary flow reserve (CFR) may be helpful in assessing the functional status of coronary vessels in order to determine disease severity

and effectiveness of implemented therapies [7–10]. The haemodynamic significance of lesions in epicardial vessels has been characterized by invasive techniques such as intracoronary Doppler which provide a direct assessment of coronary flow velocity and relative flow reserve [11, 12]. Cardiac positron emission tomography (PET) allows non-invasive and accurate quantitative measurements of myocardial blood flow (MBF) and CFR [13–15]. PET-based measurement of MBF is useful to assess coronary vasomotor alterations and preclinical but evolving atherosclerosis. However, PET technology has not been routinely employed because of economic and logistic constraints. In this context, SPECT with  $^{99m}\text{Tc}$ -labelled tracers has played a key role for the evaluation of myocardial perfusion in patients with CAD [1–4]. Recently, efforts to estimate CFR with SPECT tracers have produced encouraging results [16–29]. In particular, a good agreement of this technique with the results obtained by invasive methods has been showed [16, 18, 19]. However, when this procedure is applied several issues might affect absolute quantitation: some related to low-resolution factors and others dealing with the accuracy of measuring arterial input function. In particular, by using dynamic planar imaging the measurement of input function may be affected by the spillover from adjacent structures and it is not possible to separate the contribution of the myocardium from the left ventricular (LV) chamber blood as well as to avoid the interference of the right ventricle and aorta. The aim of this study was to compare two different computing methods for the estimation of CFR by SPECT imaging with the results of intracoronary Doppler technique in patients with CAD.

## Materials and methods

### Study population

This study included 14 consecutive patients (11 men, mean age:  $54 \pm 7$  years) with documented CAD in whom percutaneous coronary intervention was planned. No patients had echocardiographic evidence of LV hypertrophy. Two patients had diabetes mellitus and three patients systemic arterial hypertension. At the time of the study, all patients were in clinically stable condition, and patients were taking  $\beta$ -blockers ( $n=3$ ), angiotensin-converting enzyme inhibitors ( $n=3$ ) and nitrates ( $n=6$ ). Patients with previous myocardial infarction were excluded. Within 5 days, all patients underwent an intracoronary Doppler study and  $^{99m}\text{Tc}$ -sestamibi imaging. No clinical modification occurred or therapy change was adopted between the SPECT and the Doppler study. All patients were carefully instructed to refrain from oral intake of methylxanthines, including caffeine, during the 24 h before the SPECT and Doppler

studies under dipyridamole stress. Global CFR and that computed in the culprit vessel of such patients has already been compared with CFR measured in corresponding territories of subjects with suspected CAD and normal vessels at coronary angiography in our laboratory [16]. The Ethics Committee of our university approved the protocol, and each patient gave informed consent.

### Sestamibi imaging

All patients underwent dipyridamole and rest cardiac imaging. Dipyridamole was infused intravenously at a dose of 0.74 mg/kg body weight given over a 6-min period with monitoring of symptoms, blood pressure and 12-lead electrocardiography [30]. No patients had severe angina or hypotension or developed other intolerable side effects.  $^{99m}\text{Tc}$ -sestamibi, 555 MBq, was injected intravenously as a bolus 1–2 min before completion of the stress test. Dynamic planar images were acquired for 60 s (4 frames/s) in the anterior view to measure the first transit counts in the pulmonary artery (PA) and in the LV chamber. SPECT imaging was performed 60 min later. Data were acquired with a rotating single-head gamma camera (Elscont SP4HR, Elscint, Haifa, Israel) connected with a dedicated computer system. Thirty-two projections (30 s/projection) were obtained over a semicircular  $180^\circ$  arc, which extended from the  $30^\circ$  right anterior oblique to the left posterior oblique position. A 20% symmetric energy window centred on the 140-keV peak was used. Filtered backprojection was then performed with a low-resolution Butterworth filter with a cut-off frequency of 0.5 cycles per pixel and order of 5.0. No attenuation or scatter correction was applied. Rest imaging was performed on a separate day following the same acquisition protocol.

For first-pass analysis, serial images of the first transit study were evaluated frame by frame, and on the summed image (3–5 s duration),  $3 \times 2$ -pixel regions of interest (ROI) were assigned at the main right PA and at LV chamber. After algorithm smoothing over a mean of 3 points, the area under the time-activity curve was calculated to obtain the time integral of the first-pass tracer counts for both PA and LV ( $\int [C(t)dt]$ ). Sestamibi activity was measured on two representative short-axis tomograms (at mediobasal and medioapical levels). For each short-axis tomogram, a global ROI including the whole myocardial thickness was assigned. In addition, each tomogram was divided into six sectors of equal arc, representing the anterolateral, lateral, inferior, posteroseptal, septal and anterior myocardium, and a regional ROI was located in the corresponding sector. Tracer activity was expressed as absolute myocardial counts, and mean tracer uptake for each major coronary territory was calculated. Counts from PA, LV and myocardium were not corrected for background. To directly

compare the results of sestamibi imaging with those of intracoronary Doppler, each segment was assigned to one of the major vascular territories. In brief, the left anterior descending artery territory included the anterior and anterolateral walls and septum. The right coronary artery was assigned the posteroseptal and inferior walls. The left circumflex artery was assigned the lateral wall. Estimated MBF under stress and resting conditions was measured as myocardial counts/ $\int [C(t)dt]$  considering the input function obtained from both right PA and LV. It was expressed as counts/pixel per s. Estimated CFR was expressed as the ratio of stress MBF to rest MBF. The accuracy and reproducibility of this method have been previously reported [16].

#### Intracoronary Doppler study

Intracoronary CFR measurements with Doppler guide wires were performed in stenotic vessels in which percutaneous coronary intervention was planned immediately before treatment. In brief, CFR was continuously evaluated starting at baseline and during dipyridamole infusion. As for sestamibi imaging, dipyridamole was infused intravenously at a dose of 0.74 mg/kg body weight given over a 6-min period with monitoring of symptoms, blood pressure and 12-lead electrocardiography [30]. No patients developed severe angina, hypotension or other intolerable side effects. FloMap 5500 (Cardiometrics Inc., Rancho Cordova, CA, USA) and Doppler flow wire (0.014-inch, 12-MHz FloWire, Cardiometrics Inc., Rancho Cordova, CA, USA) were used. The tip of the flow wire was carefully positioned as distally as possible and, in any case, beyond the stenosis. Intravascular velocity measurement was achieved at rest and during maximal vasodilatation induced by dipyridamole infusion. CFR was calculated by the ratio of mean maximal systolic-diastolic velocity at hyperaemia to the corresponding

velocity at rest, by use of a machine-incorporated software system. Examinations were recorded on S-VHS videotape.

#### Statistical analysis


Continuous data were expressed as mean  $\pm$  SD. One-way analysis of variance (ANOVA) was used for comparing means between groups. Post hoc analysis with Bonferroni correction was performed. Differences between mean values were assessed by Student's *t* test (two-tailed probability) for paired data. Linear regression analysis was used to assess the relationship between CFR estimated by sestamibi using ROI on both PA and LV and by the intracoronary Doppler technique. A *p* value  $<$  0.05 was considered statistically significant. Bland-Altman analysis was also used to evaluate the agreement between the techniques [31]. With this method, the differences between two techniques are plotted against the means of the two techniques. If the limits of agreement (mean  $\pm$  1.96 times the SD of the differences) are not clinically important, the two methods may be considered interchangeable.

#### Results

In each patient, Doppler flow velocity was measured in stenotic vessels in which percutaneous coronary intervention was planned. The individual study vessels and the degree of coronary artery stenosis are shown in Table 1. In the study vessel, SPECT-estimated rest and stress MBF obtained using first transit counts from PA were higher as compared to that from LV chamber (rest:  $1.05 \pm 0.38$  vs  $0.87 \pm 0.34$  counts/pixel per s, respectively,  $p < 0.01$  and stress:  $1.34 \pm 0.45$  vs  $0.91 \pm 0.20$  counts/pixel per s, respectively,  $p < 0.05$ ) (Fig. 1).

**Table 1** Individual study vessel and degree of coronary artery stenosis from patients undergoing CFR assessment by sestamibi imaging and intracoronary Doppler


Patient	Study vessel	Coronary artery stenosis (%)
1	Right coronary artery	75
2	Left circumflex coronary artery	75
3	Left anterior descending coronary artery	90
4	Left anterior descending coronary artery	85
5	Left anterior descending coronary artery	90
6	Right coronary artery	75
7	Right coronary artery	75
8	Left anterior descending coronary artery	75
9	Left anterior descending coronary artery	75
10	Left anterior descending coronary artery	75
11	Right coronary artery	65
12	Left circumflex coronary artery	60
13	Left anterior descending coronary artery	70
14	Left anterior descending coronary artery	65




**Fig. 1** Stress and rest values of <sup>99m</sup>Tc-sestamibi-estimated myocardial blood flow (MBF) obtained using first transit counts from pulmonary artery and left ventricle

CFR measured by intracoronary Doppler was  $1.39 \pm 0.43$ , and corresponding SPECT-estimated CFR obtained using first transit counts from PA and LV chamber were  $1.36 \pm 0.51$  and  $1.16 \pm 0.33$ , respectively ( $p$  across categories NS). A significant relationship between SPECT-estimated CFR obtained using first transit counts from PA and CFR by intracoronary Doppler was found ( $r = 0.85$ ,  $p < 0.001$ ) (Fig. 2). On the contrary, no relationship between SPECT-estimated CFR obtained using first transit counts from LV chamber and CFR by intracoronary Doppler was observed ( $r = 0.23$ ,  $p = \text{NS}$ ) (Fig. 3).

The mean difference between SPECT-estimated CFR obtained using first transit counts from PA and by intracoronary Doppler was 0.02, the SD of differences 0.23, and the lower and upper limits of agreement between the two techniques were  $-0.44$  and  $0.48$ , respectively (Fig. 4). On the other hand, the mean difference between SPECT-estimated CFR obtained using first transit counts from LV chamber and by intracoronary Doppler was 0.22, the SD of differences 0.33, and the lower and upper limits of agreement between the two techniques were  $-0.71$  and  $1.16$ , respectively (Fig. 5).



**Fig. 2** Relationship between <sup>99m</sup>Tc-sestamibi-estimated CFR obtained using first transit counts from the pulmonary artery (PA) and intracoronary Doppler CFR




**Fig. 3** Relationship between <sup>99m</sup>Tc-sestamibi-estimated CFR obtained using first transit counts from the left ventricle (LV) and intracoronary Doppler CFR


**Discussion**

Our results demonstrate that, in patients with documented CAD, CFR estimated by SPECT sestamibi imaging using first transit counts from PA is more accurate and correlates better with the results of intracoronary Doppler than CFR obtained using first transit counts from LV chamber. This study has also shown a reduction in both stress and rest estimated MBF when first transit counts are obtained from LV chamber.

The feasibility of CFR measurement has been widely investigated and its value well recognized. Gould and Lipscomb [32] originally outlined the importance of measuring CFR in clinical practice and were the first to define the relationship between CFR and the severity of coronary stenosis. Although there are some limitations,



**Fig. 4** Agreement between <sup>99m</sup>Tc-sestamibi-estimated CFR obtained using first transit counts from the pulmonary artery (PA) and intracoronary Doppler CFR by Bland-Altman analysis. The differences between the two techniques are plotted against the means of the two techniques. The horizontal solid line indicates the mean difference between the two techniques, and the dashed lines indicate the limits of agreement (mean difference  $\pm 1.96$  times the SD of the difference)



**Fig. 5** Agreement between  $^{99m}\text{Tc}$ -sestamibi-estimated CFR obtained using first transit counts from the left ventricle (LV) and intracoronary Doppler CFR by Bland-Altman analysis. The differences between the two techniques are plotted against the means of the two techniques. The *horizontal solid line* indicates the mean difference between the two techniques, and the *dashed lines* indicate the limits of agreement (mean difference  $\pm 1.96$  times the SD of the difference)

CFR measures can be achieved with both invasive and non-invasive procedures [22, 33–40]. Intravascular Doppler ultrasound transducer or pressure transducer attached to the end of an angioplasty guide wire system, once the system is placed into the coronary artery of interest, allows assessing CFR invasively [11, 40, 41]. Essentially, this technique evaluates coronary flow velocity reserve, which is the ratio of intracoronary mean velocity under baseline conditions to mean velocity after pharmacological induction of maximal hyperaemia. Because blood velocity is proportional to flow for a constant vessel area, coronary flow velocity reserve may be calculated from the hyperaemic flow divided by resting blood velocity in a vessel. In our study an intracoronary Doppler wire was used to assess CFR. No angiography was performed at the time of the maximal effect of the dipyridamole infusion avoiding changes in the lumen diameter of the coronary artery at the site of Doppler measurements, which would have affected volumetric flow assessment. Nevertheless, it has been demonstrated that no change or minimal changes occur in coronary diameter after intravenous adenosine or dipyridamole administration and that slight vasodilatation may occur in both normal and stenotic segments; as a result, the percent diameter stenosis is not essentially altered [42–44]. PET and SPECT represent non-invasive methods to evaluate CFR. In particular, PET imaging with  $^{15}\text{O}$  water [13–15, 39] and  $^{13}\text{N}$  ammonia [45, 46] represents the non-invasive gold standard for obtaining quantitative regional blood flow and CFR, whereas  $^{82}\text{Rb}$  has been more recently proposed as a possible agent for these purposes [47, 48]. However, both intracoronary Doppler and cardiac

PET, because of their economic constraints and complicated measures, may not be applied routinely in clinical assessment. Recently, estimates of CFR with single photon tracers achieved good agreement with the results obtained by invasive methods [16, 19], even if Taki et al. [18] demonstrated that the increase in myocardial retention of  $^{99m}\text{Tc}$ -labelled agents underestimates CFR at high flow rates. For patients with CAD we reported that sestamibi imaging is an accurate and simple way to non-invasively estimate CFR with good interobserver and intraobserver reproducibility [16]. This procedure is based on the microsphere method, which makes use of the fact that sestamibi is taken up by the myocardium according to blood flow. Factors related to low resolution, such as scatter, attenuation and partial volume effects, hamper the absolute quantitation of both arterial and tissue counts, but they may be cancelled out by computing the ratio of tissue and arterial counts. In addition, first-pass studies have intrinsic difficulties such as the need for bolus integrity to obtain best-fit gamma function or the individual characteristics of great vessel anatomy in the adult population [49]. Another important factor affecting the accuracy of estimates is the noise characteristics inherent to dynamic studies. It can be a result of the movement of the patient within the scanner and respiratory movement, as well as cardiac motion.

From a methodological point of view, the procedure chosen to obtain the arterial input function seems to represent one of the most critical factors affecting the accuracy of measurements. In fact, the use of a ROI assigned either to the PA or to the ascending aorta has been alternatively sustained in the estimation of MBF [17, 19, 20]. Provided that appropriate ROI are selected, first-pass studies can yield reasonably accurate and reproducible determinations of cardiac output. The use of a ROI designed on the ascending aorta to measure first transit counts was supported by Ito et al. [9] since this technique may have the potential for greater reproducibility and be less dependent on the bolus administration than is measurement of the first transit counts in the PA. Conversely, the method might have the potential to cause a relatively large error in patients who have low cardiac output with a very slow time-activity curve of the aorta. In the present study all patients had an adequate time-activity curve without insufficient bolus and none of them had impaired LV function. This latter imaging approach was likely gathered from PET studies [50–53], which used a blood time-activity curve derived from a ROI drawn over dynamic PET images of the left ventricle. Results from these studies indicate that the time-activity curve obtained from the LV ROI matched well with the arterial plasma curve. It should be taking into account that ascending aorta and left ventricle represent a unique comprehensive

dynamic system as ventricular/vascular coupling can be assessed from measurements of pressure and flow in the ascending aorta (for left ventricle/systemic circulation) [54]. The integrated model of the left ventricle and aorta has been postulated theoretically [55], studied in animals [56] and investigated in humans by means of magnetic resonance [57]. Another method promotes the use of a right PA ROI to compute the arterial input function for the myocardial perfusion measurements [16, 17]. Although it assumes that the relative proportion of the tracer entering the right PA does not differ between the pharmacological stress and rest studies, differences could be detected in patients with advanced obstructive pulmonary disease or with other diseases affecting the lungs. As a result, both the above-mentioned procedures used to compute arterial input function appear to retain some concerns.

In our study we compared the values of CFR estimated by sestamibi obtained using first transit counts from both PA and LV chamber with those derived from intracoronary Doppler. Although no significant differences were found in CFR measures between the three methods, a significant relationship between CFR estimated by sestamibi using first transit counts from PA and CFR obtained by intracoronary Doppler was observed. On the contrary, no relationship between CFR estimated by sestamibi using first transit counts from LV chamber and CFR obtained by intracoronary Doppler was found. Thus, the accuracy of the arterial input function was improved by assigning a ROI at the right PA. These results endorse the concept that spillover from bordering cardiac structures may affect the accuracy of measurement by sestamibi imaging when the blood pool time-activity curve is derived from a ROI drawn in the ascending aorta or in the LV chamber. Spillover from tissue to the LV blood pool at late times is a more complicated factor when the LV curve is to be used as an input function in PET studies [49]. It depends on the usually high extraction rate of positron-emitting tracers, which does not represent a critical factor when SPECT tracers are used to obtain dynamic images. However, using sestamibi imaging, spillover to the left ventricle from the right ventricle, and atria or to the ascending aorta from the surrounding cardiac structures, should be usually encompassed. In addition, because most acquiring incidences enclose the most part of cardiac chambers some of the noise problems associated with the cardiac motion might not be completely ruled out. To substantiate this hypothesis, we considered SPECT-estimated stress and rest MBF obtained using first transit counts from PA, which were higher as compared to that from the left ventricle. A reduction in both stress and rest MBF accounts for the occurrence of spillover from bordering cardiac structures when left ventricle or ascending aorta is used. Accordingly, CFR estimated by sestamibi imaging obtained using first transit counts from

PA correlated well with the results of intracoronary Doppler. Finally, it should be considered that the type of stress might influence CFR measurements [58, 59]. In our study protocol CFR was evaluated by use of dipyridamole for stress testing during both radionuclide imaging and intracoronary Doppler with similar haemodynamic changes [16]. Dipyridamole can be infused at low, intermediate and high dose [30]. Previous studies showed that the effect of intermediate- and high-dose testing does not carry a greater risk than low-dose testing [30, 60]. For the purpose of the current study we employed an intermediate (0.74 mg/kg) dipyridamole dosage.

## Conclusion

SPECT-estimated CFR obtained using arterial input function from right PA counts is more accurate and correlates better with the results of intracoronary Doppler than estimated CFR obtained using arterial input function from LV chamber. Thus, the accuracy of arterial input function may be improved by assigning a ROI at PA, avoiding spillover from bordering cardiac structures that can be observed using the LV chamber.

## References

- Nicolai E, Cuocolo A, Pace L, Nappi A, Sullo P, Cardei S, et al. Adenosine coronary vasodilatation quantitative technetium 99m methoxy isobutyl isonitrile myocardial tomography in the identification and localization of coronary artery disease. *J Nucl Cardiol* 1996;3:9–17. doi:10.1016/S1071-3581(96)90019-7.
- Miller DD, Younis LT, Chaitman BR, Stratmann H. Diagnostic accuracy of dipyridamole technetium 99m-labelled sestamibi myocardial tomography for detection of coronary artery disease. *J Nucl Cardiol* 1997;4:18–24. doi:10.1016/S1071-3581(97)90045-3.
- Heller GV, Herman SD, Travin MI, Baron JI, Santos-Ocampo C, McClellan JR. Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions. *J Am Coll Cardiol* 1995;26:1202–8. doi:10.1016/0735-1097(95)00329-0.
- Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Amato M, Miller DD. Prognostic value of predischarge dipyridamole technetium 99m sestamibi myocardial tomography in medically treated patients with unstable angina. *Am Heart J* 1995;130:734–40. doi:10.1016/0002-8703(95)90071-3.
- Garcia EV. Quantitative myocardial perfusion single-photon emission computed tomographic imaging: quo vadis? *J Nucl Cardiol* 1994;1:83–93. doi:10.1007/BF02940015.
- Germano G. Technical aspects of myocardial SPECT imaging. *J Nucl Med* 2001;42:1499–507.
- Klocke FJ. Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care. *Circulation* 1987;76:1183–9.
- Hoffman JI. A critical view of coronary reserve. *Circulation* 1987;75:16–11.
- Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response

- and regional distribution during coronary hyperemia as measures of coronary flow reserve. *Am J Cardiol* 1974;33:87–94. doi:10.1016/0002-9149(74)90743-7.
10. Baller D, Notohamprojo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. *Circulation* 1999;99:2871–5.
  11. Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. *Circulation* 1992;85:1899–911.
  12. Aude YW, Garza L. How to prevent unnecessary coronary interventions: identifying lesions responsible for ischemia in the cath lab. *Curr Opin Cardiol* 2003;18:394–9. doi:10.1097/00001573-200309000-00012.
  13. Bergmann SR, Fox KA, Rand AL, McElvany KD, Welch MJ, Markham J, et al. Quantification of regional myocardial blood flow in vivo with H215O. *Circulation* 1984;70:724–33.
  14. Araujo LI, Lammertsma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, et al. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. *Circulation* 1991;83:875–85.
  15. Iida H, Kanno I, Takahashi A, Miura S, Murakami M, Takahashi K, et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. *Circulation* 1988;78:104–15.
  16. Storto G, Cirillo P, Vicario ML, Pellegrino T, Sorrentino AR, Petretta M, et al. Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: comparison with the results of intracoronary Doppler technique. *J Nucl Cardiol* 2004;11:682–8. doi:10.1016/j.nuclcard.2004.08.007.
  17. Sugihara H, Yonekura Y, Kataoka K, Fukai D, Kitamura N, Taniguchi Y. Estimation of coronary flow reserve with the use of dynamic planar and SPECT images of Tc-99m tetrofosmin. *J Nucl Cardiol* 2001;8:575–9. doi:10.1067/mnc.2001.115934.
  18. Taki J, Fujino S, Nakajima K, Matsunari I, Okazaki H, Saga T, et al. (99m)Tc-sestamibi retention characteristics during pharmacologic hyperemia in human myocardium: comparison with coronary flow reserve measured by Doppler flowwire. *J Nucl Med* 2001;42:1457–63.
  19. Ito Y, Katoh C, Noriyasu K, Kuge Y, Furuyama H, Morita K, et al. Estimation of myocardial blood flow and myocardial flow reserve by 99mTc-sestamibi imaging: comparison with the results of [15O]H2O PET. *Eur J Nucl Med Mol Imaging* 2003;30:281–7.
  20. Brunken RC. Challenges for measurement of myocardial perfusion and perfusion reserve by SPECT imaging. *J Nucl Cardiol* 2007;14:145–9. doi:10.1016/j.nuclcard.2007.01.034.
  21. Ragosta M. The clinical assessment of coronary flow reserve in patients with coronary artery disease. *J Nucl Cardiol* 2004;11:651–5. doi:10.1016/j.nuclcard.2004.09.010.
  22. Gullberg GT, Di Bella EV, Sinusas AJ. Estimation of coronary flow reserve: can SPECT compete with other modalities? *J Nucl Cardiol* 2001;8:620–5. doi:10.1067/mnc.2001.118121.
  23. Vicario ML, Cirillo L, Storto G, Pellegrino T, Ragone N, Fontanella L, et al. Influence of risk factors on coronary flow reserve in patients with 1-vessel coronary artery disease. *J Nucl Med* 2005;46:1438–43.
  24. Pellegrino T, Storto G, Filardi PP, Sorrentino AR, Silvestro A, Petretta M, et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. *J Nucl Med* 2005;46:1997–2002.
  25. Storto G, Pellegrino T, Sorrentino AR, Luongo L, Petretta M, Cuocolo A. Estimation of coronary flow reserve by sestamibi imaging in type 2 diabetic patients with normal coronary arteries. *J Nucl Cardiol* 2007;14:194–9. doi:10.1016/j.nuclcard.2006.12.327.
  26. Perrone-Filardi P, Cuocolo A, Brevetti G, Silvestro A, Storto G, Dellegrottaglie S, et al. Relation of brachial artery flow-mediated vasodilation to significant coronary artery disease in patients with peripheral arterial disease. *Am J Cardiol* 2005;96:1337–41. doi:10.1016/j.amjcard.2005.06.084.
  27. Storto G, Sorrentino AR, Pellegrino T, Liuzzi R, Petretta M, Cuocolo A. Assessment of coronary flow reserve by sestamibi imaging in patients with typical chest pain and normal coronary arteries. *Eur J Nucl Med Mol Imaging* 2007;34:1156–61. doi:10.1007/s00259-006-0333-x.
  28. Palmieri V, Storto G, Arezzi E, Pellegrino T, Mancini M, Di Minno G, et al. Relations of left ventricular mass and systolic function to endothelial function and coronary flow reserve in healthy, new discovered hypertensive subjects. *J Hum Hypertens* 2005;19:941–50. doi:10.1038/sj.jhh.1001921.
  29. Petretta M, Soricelli A, Storto G, Cuocolo A. Assessment of coronary flow reserve using single photon emission computed tomography with technetium 99m-labeled tracers. *J Nucl Cardiol* 2008;15:456–65. doi:10.1016/j.nuclcard.2008.03.008.
  30. Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al. Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. *J Nucl Cardiol* 1995;2:3–17. doi:10.1016/S1071-3581(05)80003-0.
  31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;1:307–10.
  32. Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. *Am J Cardiol* 1974;34:48–55. doi:10.1016/0002-9149(74)90092-7.
  33. Marcus ML, Wilson RF, White CW. Methods of measurement of myocardial blood flow in patients: a critical review. *Circulation* 1987;76:245–53.
  34. Hoffman JI. Problems of coronary flow reserve. *Ann Biomed Eng* 2000;28:884–96. doi:10.1114/1.1308503.
  35. De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. *Circulation* 1994;89:1013–22.
  36. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, et al. Coronary flow reserve measurement with transthoracic Doppler echocardiography is reproducible and comparable with positron emission tomography. *Clin Physiol* 2001;21:114–22. doi:10.1046/j.1365-2281.2001.00296.x.
  37. Germain P, Roul G, Baruthio J, Jahn C, Coulbois PM, Dumitresco B, et al. Myocardial flow reserve parametric map, assessed by first-pass MRI compartmental analysis at the chronic stage of infarction. *J Magn Reson Imaging* 2001;13:352–60. doi:10.1002/jmri.1050.
  38. Koskenvuo JW, Sakuma H, Niemi P, Toikka JO, Knuuti J, Laine H, et al. Global myocardial blood flow reserve measurements by MRI and PET are comparable. *J Magn Reson Imaging* 2001;13:361–6. doi:10.1002/jmri.1051.
  39. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. *J Am Coll Cardiol* 1989;14:639–52.
  40. Joye JD, Schulman DS. Clinical application of coronary flow reserve using an intracoronary Doppler guide wire. *Cardiol Clin* 1997;15:101–29. doi:10.1016/S0733-8651(05)70321-0.
  41. Labovitz AJ, Anthonis DM, Cravens TL, Kern MJ. Validation of volumetric flow measurements by means of a Doppler-tipped coronary angioplasty guide wire. *Am Heart J* 1993;126:1456–61. doi:10.1016/0002-8703(93)90545-K.
  42. Kern MJ, Deligonul U, Tatineni S, Serota H, Aguirre F, Hilton TC. Intravenous adenosine: continuous infusion and low dose bolus administration for determination of coronary vasodilator reserve in

- patients with and without coronary artery disease. *J Am Coll Cardiol* 1991;18:718–29.
43. Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilatation with intravenous dipyridamole and adenosine. *J Am Coll Cardiol* 1991;18:485–91.
  44. Ogilby JD, Iskandrian AS, Untereker WJ, Heo J, Nguyen TN, Mercuro J. Effect of intravenous adenosine infusion on myocardial perfusion and function. Hemodynamic/angiographic and scintigraphic study. *Circulation* 1992;86:887–95.
  45. Masuda D, Nohara R, Tamaki N, Hosokawa R, Inada H, Hikai T, et al. Evaluation of coronary blood flow reserve by <sup>13</sup>N-NH<sub>3</sub> positron emission computed tomography (PET) with dipyridamole in the treatment of hypertension with the ACE inhibitor (Cilazapril). *Ann Nucl Med* 2000;14:353–60. doi:10.1007/BF02988695.
  46. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. *Circulation* 1996;94:3232–8.
  47. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with <sup>82</sup>Rb dynamic PET imaging. *Eur J Nucl Med Mol Imaging* 2007;34:1765–74. doi:10.1007/s00259-007-0478-2.
  48. Lautamäki R, George RT, Kitagawa K, Higuchi T, Merrill J, Voicu C, et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. *Eur J Nucl Med Mol Imaging* 2009;36:576–86. doi:10.1007/s00259-008-0972-1.
  49. Castell-Conesa J, Candell-Riera J. Estimation of coronary flow reserve by SPECT: myth or reality? *Eur J Nucl Med Mol Imaging* 2007;34:1152–5. doi:10.1007/s00259-007-0415-4.
  50. Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. *J Nucl Med* 1989;30:359–66.
  51. Santana CA, Folks RD, Garcia EV, Verdes L, Sanyal R, Hainer J, et al. Quantitative (<sup>82</sup>Rb) PET/CT: development and validation of myocardial perfusion database. *J Nucl Med* 2007;48:1122–8. doi:10.2967/jnumed.107.039750.
  52. Katoh C, Morita K, Shiga T, Kubo N, Nakada K, Tamaki N. Improvement of algorithm for quantification of regional myocardial blood flow using <sup>15</sup>O-water with PET. *J Nucl Med* 2004;45:1908–16.
  53. Choi Y, Hawkins RA, Huang SC, Gambhir SS, Brunken RC, Phelps ME, et al. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[<sup>18</sup>F] fluoro-2-deoxy-d-glucose studies. *J Nucl Med* 1991;32:733–8.
  54. O'Rourke MF, Yaginuma T, Avolio AP. Physiological and pathophysiological implications of ventricular/vascular coupling. *Ann Biomed Eng* 1984;12:119–34. doi:10.1007/BF02584226.
  55. Nakamura M, Wada S, Yamaguchi T. Computational analysis of blood flow in an integrated model of the left ventricle and the aorta. *J Biomech Eng* 2006;128:837–43. doi:10.1115/1.2400864.
  56. Perlini S, Soldà PL, Piepoli M, Calciati A, Paro M, Marchetti G, et al. Time course of pressure and flow in ascending aorta during ejection. *Int J Cardiol* 1991;30:169–79. doi:10.1016/0167-5273(91)90092-4.
  57. Long Q, Merrifield R, Xu XY, Kilner P, Firmin DN, G-Z Y. Subject-specific computational simulation of left ventricular flow based on magnetic resonance imaging. *Proc Inst Mech Eng [H]* 2008;222:475–85. doi:10.1243/09544119JEIM310.
  58. McGinn AL, White CW, Wilson RF. Interstudy variability of coronary flow reserve. Influence of heart rate, arterial pressure, and ventricular preload. *Circulation* 1990;81:1319–30.
  59. Scherhag AW, Pflieger S, de Mey C, Schreckenberger AB, Staedt U, Heene DL. Continuous measurement of hemodynamic alterations during pharmacologic cardiovascular stress using automated impedance cardiography. *J Clin Pharmacol* 1997;37(Suppl):21S–8S. doi:10.1177/009127009703700118.
  60. Varga A, Garcia MA, Picano E, International Stress Echo Complication Registry. Safety of stress echocardiography (from the International Stress Echo Complication Registry). *Am J Cardiol* 2006;98:541–3. doi:10.1016/j.amjcard.2006.02.064.